# Daniel B. Costa

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/daniel-b-costa/

## Facts

| Field | Value |
| --- | --- |
| Citations | 26,598 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 61 |
| i10-index | 150 |
| Last Known Institution | Beth Israel Deaconess Medical Center |
| OpenAlex ID | https://openalex.org/A5042156692 |
| ORCID iD | https://orcid.org/0000-0002-0689-395X |
| Works | 359 |

## Researcher papers

- [Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer](https://scholariq.org/papers/anaplastic-lymphoma-kinase-inhibition-in-non-small-cell-lung-cancer/)
- [Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/crizotinib-in-i-ros1-i-rearranged-non-small-cell-lung-cancer/)
- [Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor <i>EML4-ALK</i>](https://scholariq.org/papers/clinical-features-and-outcome-of-patients-with-non-small-cell-lung-cancer-who/)
- [Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints](https://scholariq.org/papers/adaptive-resistance-to-therapeutic-pd-1-blockade-is-associated-with-upregulation/)
- [Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study](https://scholariq.org/papers/activity-and-safety-of-crizotinib-in-patients-with-alk-positive-non-small-cell/)
- [Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis](https://scholariq.org/papers/effect-of-crizotinib-on-overall-survival-in-patients-with-advanced-non-small/)
- [Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib](https://scholariq.org/papers/assessment-of-resistance-mechanisms-and-clinical-implications-in-patients-with-i/)
- [RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer](https://scholariq.org/papers/rb-loss-in-resistant-egfr-mutant-lung-adenocarcinomas-that-transform-to-small/)
- [Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer](https://scholariq.org/papers/structural-biochemical-and-clinical-characterization-of-epidermal-growth-factor/)
- [A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response](https://scholariq.org/papers/a-murine-lung-cancer-co-clinical-trial-identifies-genetic-modifiers-of/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Beth Israel Deaconess Medical Center](https://scholariq.org/institutions/beth-israel-deaconess-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.